your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com
Uptodate Reference Title
HER2 assessment for breast cancer
HER2 assessment for breast cancer
HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; ISH: in situ hybridization. * ISH should be recounted by an additional observer, blinded to previous ISH results; count should be at least 20 cells that include the area of invasive cancer with IHC 2+ staining. ΒΆ The predictive value of this finding of benefit from anti-HER2 therapy is unknown, and it therefore is also reasonable to omit anti-HER2 therapy.